CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenues
Collaboration revenue	$ 0	$ 0	$ 0	$ 43,000
Total revenues	0	0	0	43,000
Operating expenses
Research and development	6,281,000	1,478,000	28,006,000	4,760,000
In-process research and development	0	7,000,000	0	7,000,000
General and administrative	4,508,000	1,704,000	15,450,000	5,760,000
Total operating expenses	10,789,000	10,182,000	43,456,000	17,520,000
Loss from operations	(10,789,000)	(10,182,000)	(43,456,000)	(17,477,000)
Other income (expense)
Interest income	5,000	0	15,000	0
Interest expense	(19,000)	(292,000)	(59,000)	(555,000)
Other income (expense)	(4,000)	0	(336,000)	0
Total other income (expense)	(18,000)	(292,000)	(380,000)	(555,000)
Loss before income taxes	(10,807,000)	(10,474,000)	(43,836,000)	(18,032,000)
Income tax benefit	(52,000)	0	(52,000)	0
Net loss and comprehensive loss	(10,755,000)	(10,474,000)	(43,784,000)	(18,032,000)
Net loss	(10,755,000)	(10,474,000)	(43,784,000)	(18,032,000)
Deemed dividend related to Warrant Exchange	0	0	0	(12,546,000)
Net loss to common stockholders	$ (10,755,000)	$ (10,474,000)	$ (43,784,000)	$ (30,578,000)
Shares used in calculating net loss per common share - basic (in shares)	198,790,980	141,591,218	193,599,525	92,764,157
Shares used in calculating net loss per common share - diluted (in shares)	198,790,980	141,591,218	193,599,525	92,764,157
Net loss per share of common stock - basic (in USD per share)	$ (0.05)	$ (0.07)	$ (0.23)	$ (0.33)
Net loss per share of common stock - diluted (in USD per share)	$ (0.05)	$ (0.07)	$ (0.23)	$ (0.33)